Expression of CD28+and CD56+in Patients with Multiple Myeloma and Its Evaluation Value on Prognosis
Objective To analyze the expression of CD28+and CD56+in patients with multiple myeloma(MM)and its evaluation value on prognosis.Methods 103 patients with MM were included.The expression of CD28 and CD56 was detected on admission.The prognosis results were followed up for 2 years.The data of patients with different prognosis(survival and death)were compared.COX was used to analyze the prognostic factors of MM patients.The correlation between CD28 and CD56 expres-sion and international staging system(R-ISS)stage and β2-microglobulin(β2-MG)of MM patients was analyzed.DCA curve was drawn to analyze the value of CD28+and CD56+expression in predicting the prognosis of MM patients.Results Among 103 MM patients,a total of 19 cases of MM patients died within 2 years,and 84 cases survived.The 2-year survival rate was 81.55％(84/103).Cox analysis showed that R-ISS stage Ⅲ,β2-MG,CD28 and CD56 were the influencing factors of death in MM patients(HR＞1,P＜0.05).Kendall's tau-b correlation analysis showed that CD28+and CD56+were positively correlated with R-ISS stage in MM patients(P＜0.05).Spearson correlation analysis showed that,the expression of CD28+was positively correlated with the lev-el of β2-MG in MM patients(P＜0.05),the expression of CD56+was not correlated with the level of β2-MG in MM patients(P＞0.05).DCA curve analysis showed that when the high-risk threshold was 0.0-0.31,the net benefit rate of CD28+and CD56+ex-pression in predicting the prognosis of MM patients was greater than 0,which was of clinical significance,and the maximum net benefit rate was 0.184.Conclusion The abnormal expression of CD28+and CD56+in MM patients has certain predictive value for prognosis.
NETL
NSTL
万方数据
